Interestingly, this aligns with clinical observations that IDH1-wt tumors often exhibit reduced sensitivity to temozolomide, as previously reported in studies showing a higher rate of temozolomide response in IDH1-mutant low-grade gliomas compared to their IDH1-wt counterparts [43]. Here, IDH1 is linked to central nervous system cancer.